Integral Molecular

52 articles with Integral Molecular

• Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

  1/7/2019

  Specific financial terms of the agreement have not been disclosed.

• Integral Molecular Announces Antibody Discovery Collaboration with Ono Pharmaceutical

  1/3/2019

  This second collaboration involves the discovery of candidate MAbs against an undisclosed target and leverages the power of Integral Molecular's MPS Antibody Discovery platform.

• Integral Molecular's Therapeutic MAbs Against CB1 to Treat NASH Enter New Development Phase Following $1.4M NIH Award

  12/4/2018

  Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome.

• Integral Molecular Awarded NIH Grant to Discover Neuroimmune Drug Targets in Alzheimer’s Disease

  11/1/2018

  Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research (SBIR) grant from the NIH to initiate a target discovery program for Alzheimer’s disease.

• 

  Researchers Continue to Develop Antivirals for Ebola, Zika, Other Infectious Diseases

  7/3/2018

  Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.

• Integral Molecular Celebrates Epitope Mapping Milestone of 1,000 Epitopes

  6/1/2018

  Integral Molecular celebrates a milestone of mapping 1,000 epitopes for customers, collaborators, and the NIH.

• Integral Molecular’s MPS Antibody Discovery Platform Yields Therapeutic Assets for Oncology and Metabolic Syndrome

  5/30/2018

  Integral Molecular announces the development of antibody assets targeting membrane proteins important in oncology (Claudin 6) and metabolic syndrome (GLUT4 and CB1).

• Integral Molecular Doubles Employee Headcount in Facility Expansion

  8/31/2017

• Integral Molecular, Inc. Announces Technology Advancement For Discovery Of New Immuno-Oncology Therapeutic Targets

  6/16/2017

• Integral Molecular, Inc. Announces The Expansion Of Its Membrane Proteome Array Technology For Improving Antibody Safety And New Target Discovery

  6/8/2017

• Integral Molecular, Inc. And Integrated BioTherapeutics Initiate Collaboration For Virus Vaccine Discovery

  3/3/2017

• Integral Molecular, Inc. Isolates Zika-Specific Monoclonal Antibodies For Vaccine Research And Diagnostics

  11/17/2016

• Integral Molecular, Inc. Launches Target Specificity Technology To Improve Safety Of Biotherapeutics

  9/22/2016

• Integral Molecular, Inc. Announces Breakthrough In Understanding The Functionality Of Gpcrs, The Largest Class Of Drug Targets In Human Disease

  8/26/2016

• Integral Molecular, Inc. Develops B-Cell Cloning Technology To Discover Rare Antibodies Against Membrane Proteins

  5/27/2016

• Integral Molecular, Inc. Expands Intellectual Property Landscape With International Patents Protecting Key Lipoparticle Technology

  2/11/2016

• DNA Immunization Expert Dr. Ross Chambers Joins Integral Molecular, Inc. To Lead Antibody Discovery

  12/11/2015

• Integral Molecular, Inc. Identifies Key Molecular Interactions Responsible For The Effectiveness Of The ZMapp Anti-Ebola Virus Cocktail

  11/13/2015

• Integral Molecular, Inc. Awarded $5.5 Million By The NIH To Study Ebola Antibodies To Aid In Vaccine Discovery

  10/15/2015

• Integral Molecular, Inc. Identifies Potent Inhibitory Antibodies Against Chikungunya Virus

  12/11/2014